FITting Non-invasive Tests in Lynch Syndrome Surveillance

The purpose of this clinical study is to evaluate the accuracy of the fecal immunochemical test (FIT) in comparison to colonoscopy in patients with Lynch Syndrome (LS) who are undergoing colonoscopy surveillance.

Trial Details

NCT ID
NCT06898996
Phase
NA
Sponsor
University of Chicago
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Fecal immunochemical test
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Ann Arbor, Michigan, United States|42.27756,-83.74088
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Have a diagnosis of LS with a confirmed pathogenic variant in MLH1, MSH2, MSH6, PMS2 or EPCAM genes.
  • Aged 20 - 80 years (for those with pathogenic variants in MLH1, MSH2, and EPCAM)
  • Aged 30 - 80 years (for those with pathogenic variants in PMS2 or MSH6).
  • Have an upcoming standard of care (SOC) colonoscopy appointment in line with standard LS surveillance guidelines (NCCN).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →